Identification of Novel Drug Targets for Alzheimer’s Disease by Integrating Genetics and Proteomes from Brain and Blood

To efficiently transform genetic associations into drug targets for Alzheimer’s disease, researchers employed an integrative analytical pipeline using proteomes in the brain and blood by systematically applying proteome-wide association study, Mendelian randomization and Bayesian colocalization.